REDWOOD CITY, Calif. — November 4, 2025 — Leads & Copy — Soleno Therapeutics, Inc. (SLNO) reported strong third-quarter results, driven by VYKAT XR sales, and provided a U.S. launch update.
Soleno achieved profitability in Q3 2025, reporting revenue of $66.0 million from VYKAT XR sales and a net income of $26.0 million. Since FDA approval on March 26, 2025, the company has received 1,043 patient start forms, with 764 active patients on the drug as of September 30, 2025, and over 132 million lives covered.
The company appointed Mark W. Hahn to its Board and raised $230 million through a common stock offering.
VYKAT XR is the first FDA-approved therapy for hyperphagia, a key symptom of Prader-Willi syndrome (PWS), in patients aged 4 and older. A conference call will be held today at 4:30 p.m. ET to discuss results.
Brian Ritchie, LifeSci Advisors, LLC, 212-915-2578
Source: Soleno Therapeutics, Inc.
